Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 50 and above, male and female starting on Pradaxa or Warfarin for nonvalvular atrial fibrillation~2. Able to ambulate independently and travel to UConn Health in Farmington CT-~Exclusion Criteria:~1. Prior known history of osteoporosis~2. Chronic kidney disease with creatinine clearance less than 30~3. Serum 25 hydroxyvitamin D level less than 10~4. Ongoing treatment with medications that interfere with bone metabolism such as steroids, bisphosonates, denosumab, estrogen, SERMS~5. Hypercalcemia, a history of Paget's disease, a history of multiple myeloma, or a history of monoclonal gammopathy of uncertain significance -

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pradaxa (Type: None): 20 men and 20 women on Pradaxa for non valvular atrial fibrillation
- Warfarin (Type: None): 20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).